However, following surgery, the immune parameters return to pretreatment levels except in those patients whose breast cancers had a pCR, when the % of NK CD3−CD16+CD56dim and NK-NKG2D+ cells continue to be significantly elevated (comparable to HFDs). The gene discussed is KLRK1; the disease is breast cancer.